Transperineal ultrasound is a good alternative for intra-fraction motion monitoring for prostate stereotactic body radiotherapy.


Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Oct 2023
Historique:
revised: 27 01 2023
received: 18 10 2022
accepted: 16 04 2023
medline: 23 10 2023
pubmed: 5 5 2023
entrez: 5 5 2023
Statut: ppublish

Résumé

To report our experience in a prospective study of implementing a transperineal ultrasound system to monitor intra-fractional prostate motion for prostate stereotactic body radiotherapy (SBRT). This IRB-approved prospective study included 23 prostate SBRT patients treated between 04/2016 and 11/2019 at our institution. The prescription doses were 36.25 Gy to the Low-Dose planning target volume (LD-PTV) and 40 Gy to the High-Dose PTV (HD-PTV) in five fractions with 3 mm planning margins. The transperineal ultrasound system was successfully used in 110 of the 115 fractions. For intra-fraction prostate motion, the real-time prostate displacements measured by ultrasound were exported for analysis. The percentage of time prostate movement exceeded a 2 mm threshold was calculated for each fraction of all patients. T-test was used for all statistical comparisons. Ultrasound image quality was adequate for prostate delineation and prostate motion tracking. The setup time for each fraction under ultrasound-guided prostate SBRT was 15.0 ± 4.9 min and the total treatment time per fraction was 31.8 ± 10.5 min. The presence of an ultrasound probe did not compromise the contouring of targets or critical structures. For intra-fraction motion, prostate movement exceeded 2 mm tolerance in 23 of 110 fractions for 11 of 23 patients. For all fractions, the mean percentage of time when the prostate moved more than 2 mm in any direction during each fraction was 7%, ranging from 0% to 62% of a fraction. Ultrasound-guided prostate SBRT is a good option for intra-fraction motion monitoring with clinically acceptable efficiency.

Identifiants

pubmed: 37144947
doi: 10.1002/acm2.14021
pmc: PMC10562017
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14021

Subventions

Organisme : NCI NIH HHS
ID : R01 CA161613
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA161613
Pays : United States

Informations de copyright

© 2023 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.

Références

Pract Radiat Oncol. 2018 May - Jun;8(3):185-202
pubmed: 29339046
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):661-9
pubmed: 22099035
Med Dosim. 2017 Winter;42(4):341-347
pubmed: 28774760
Med Phys. 2013 Jul;40(7):071707
pubmed: 23822411
Radiother Oncol. 2007 Aug;84(2):177-84
pubmed: 17706309
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1243-1252
pubmed: 28943074
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):700-6
pubmed: 22795802
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1088-98
pubmed: 17187940
Phys Med Biol. 2016 Apr 21;61(8):R90-137
pubmed: 27002558
Pract Radiat Oncol. 2016 Jul-Aug;6(4):262-267
pubmed: 26725959
Radiother Oncol. 2014 Jul;112(1):89-94
pubmed: 25023042
Phys Med Biol. 2015 Jan 21;60(2):549-63
pubmed: 25549204
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Pract Radiat Oncol. 2021 Mar-Apr;11(2):e210-e218
pubmed: 32454177
Phys Med Biol. 2013 Nov 21;58(22):7995-8006
pubmed: 24169860
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):91-100
pubmed: 11777626
J Appl Clin Med Phys. 2023 Oct;24(10):e14021
pubmed: 37144947
Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):960-964
pubmed: 27302511
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):912-921
pubmed: 29859785
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):588-94
pubmed: 25680601
Phys Med. 2016 Mar;32(3):499-505
pubmed: 26851164

Auteurs

Bingqi Guo (B)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Kevin Stephans (K)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Andrew Godley (A)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Matt Kolar (M)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Anthony Magnelli (A)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Rahul Tendulkar (R)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Omar Mian (O)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

David Majkszak (D)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Ping Xia (P)

Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH